Cécile Fermon

Cécile Fermon

Auto-generated profile, based on publicly available information

Cécile Fermon

Service de Médecine Interne, Centre Hospitalier Universitaire Edouard Herriot, Hospices Civils de Lyon , Lyon, France

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2022 in Neuromuscular Disorders
Verified
Journal Article
Closed access
CFCécile Fermon
Cécile Fermon
FAFrançois-Jérôme Authier
François-Jérôme Authier
LGLaure Gallay
Laure Gallay

22 June 2022 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
CFCécile Fermon
Cécile Fermon
TEThomas El-Jammal
Thomas El-Jammal
LKLaurent Kodjikian
Laurent Kodjikian
CBCarole Burillon
Carole Burillon
AHArnaud Hot
Arnaud Hot
PSPascal Sève
Pascal Sève

6 October 2022 in Rheumatology
Verified
Journal Article
Open access
PDF file
CFCécile Fermon
Cécile Fermon
LLLola E. R. Lessard
Lola E. R. Lessard
TFTanguy Fenouil
Tanguy Fenouil
AMAlain Meyer
Alain Meyer
MFMarie Faruch-Bilfeld
Marie Faruch-Bilfeld
LGLaure Gallay
Laure Gallay
Idiopathic inflammatory myopathies are mainly defined by inflammatory infiltrates within the muscle (lymphocytes and macrophages). Eosinophil muscle infiltration has been described in idiopathic eosinophilic myositis (IEM) and rarely in EF. This study aimed to further delineate the nosological frame of idiopathic eosinophil muscle infiltration through the exhaustive analysis of IEM and EF patients. This multicentre retrospective case series included IEM patients diagnosed between 2000 and 2022. IEM inclusion criteria were eosinophilic muscle infiltration with myositis pathological features, after the exclusion of differential diagnoses. An additional group of EF patients diagnosed between 2016 and 2022 was constituted. Inclusion criteria were an EF diagnosis and fascia thickening with inflammatory infiltrate. A total of 20 IEM cases and 10 EF cases were included. The median (interquartile range) age at diagnosis was 65 (49–70) years; there were 18 males. Data analysis delineated four subgroups: focal EM (FEM, n = 3), diffuse EM (DEM, n = 6), eosinophilic myofasciitis (EMF, n = 11) and EF (n = 10). FEM represented a limited and benign form of myositis. DEM cases presented objective muscle impairment with eosinophilic muscle infiltration. EMF patients presented subjective muscle impairment (myalgia, 55%), fasciitis (on histology and/or imaging), eosinophilic muscle infiltration and frequent hypereosinophilia (55%). EF patients presented myalgia (50%), muscle lesions on histology with fascia-restricted inflammatory infiltrates with (60%) or without (40%) eosinophils. The analysis of IEM and EF patient characteristics delineates four subgroups (FEM, DEM, EMF and EF) in terms of clinical, laboratory, imaging, pathological and outcome specificities, and proposes an adapted diagnostic and care management approach.

1 June 2021 in The American Journal of Medicine
Verified
Journal Article
Closed access
CFCécile Fermon
Cécile Fermon
MGMathieu Gerfaud-Valentin
Mathieu Gerfaud-Valentin
FDFrançois Durupt
François Durupt
Pascal SèvePascal Sève
Pascal Sève

15 June 2022 in La Revue de Médecine Interne
Verified
Journal Article
Closed access
TJT. El Jammal
T. El Jammal
CFC. Fermon
C. Fermon
Laurent KodjikianLaurent Kodjikian
Laurent Kodjikian
CBC. Burillon
C. Burillon
AHA. Hot
A. Hot
Pascal SèvePascal Sève
Pascal Sève